CELLTRION, INC.

Estimates Revisions Celltrion, Inc.

Equities

A068270

KR7068270008

End-of-day quote Korea S.E. Other stock markets 10/09/2024			5-day change	1st Jan Change
195,800.00 ^KRW	+1.93%		-0.66%	-2.83%

08-29	Celltrion Usa Partners with Express Scripts and Cigna Healthcare to Expand Access to Zymfentra® (Infliximab-Dyyb), the First and Only Fda-Approved Subcutaneous Infliximab on Their Medical Benefit Formulary	CI
08-26	European Commission Approves Celltrion's SteQeyma (CT-P43) A Biosimilar to Stelara (ustekinumab), for the Treatment of Multiple Chronic Inflammatory Diseases	CI

Turnover - Evolution of Analysts' Estimates

Earnings Per Share (EPS) - Evolution of Analysts' Estimates

EBIT - Evolution of Analysts' Estimates

Dividend / Share (DPS) - Evolution of Analysts' Estimates

Cash or Net Debt - Evolution of Analysts' Estimates

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. EPS revision	1m. Revenue rev.	1y. EPS revision	1y. Revenue rev.
	CELLTRION, INC.
	LONZA GROUP AG
	IQVIA HOLDINGS INC.
	ALNYLAM PHARMACEUTICALS, INC.
	MODERNA, INC.
	ICON PUBLIC LIMITED COMPANY
	UNITED THERAPEUTICS CORPORATION
	BIO-TECHNE CORPORATION
	MEDPACE HOLDINGS, INC.
	QIAGEN N.V.
	Average
	Weighted average by Cap.

See all sector revisions

Turnover

Estimates Revisions:

Earnings Per Share (EPS)

Estimates Revisions:

EBIT

Estimates Revisions:

Dividend / Share (DPS)

Estimates Revisions:

Cash or Net Debt

Estimates Revisions:

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW